AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Orbis international inc hr linkedin12/28/2023 ![]() The successful applicant will be resourceful, organized and motivated to increase sales, enhance the company’s reputation, and look for new and creative ways to market our products. You will work with various departments and report to the Head of Business Development. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-80.We are looking for an energetic business development associate to help drive our sales and grow the business. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. This application was granted priority review. The application reviews are ongoing at the other regulatory agencies. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), Health Canada, Singapore’s Health Sciences Authority (HSA), Switzerland’s Swissmedic, and United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. The recommended fruquintinib dose is 5 mg orally once daily, with or without food, for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. The most common adverse reactions (reported in ≥20% of patients) were hypertension, palmar-plantar erythrodysesthesia, proteinuria, dysphonia, abdominal pain, diarrhea, and asthenia. In FRESCO-2, median OS was 7.4 months (95% CI: 6.7, 8.2) for those treated with fruquintinib and 4.8 months (95% CI: 4.0, 5.8) in the placebo group (HR 0.66 p-value < 0.001). Overall survival (OS) was the major efficacy outcome in both trials. ![]() Patients received therapy until disease progression or unacceptable toxicity. In both trials patients were randomly allocated (2:1) to either fruquintinib 5 mg orally once daily or placebo for the first 21 days of each 28-day cycle plus best supportive care. FRESCO, a multicenter, placebo-controlled trial conducted in China, evaluated 416 patients with metastatic colorectal cancer who had disease progression during or after prior fluoropyrimidine-, oxaliplatin, and irinotecan-based chemotherapy. FRESCO-2 (NCT04322539), an international, multicenter, randomized, double-blind, placebo-controlled trial, evaluated 691 patients with mCRC who had disease progression during or after prior fluoropyrimidine-, oxaliplatin-, irinotecan-based chemotherapy, an anti-VEGF biological therapy an anti-EGFR biological therapy if RAS wild type, and at least one of trifluridine/tipiracil or regorafenib. View full prescribing information for fruquintinib.Įfficacy was evaluated in FRESCO-2 (NCT04322539) and FRESCO (NCT02314819). On November 8, 2023, the Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) for adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
0 Comments
Read More
Leave a Reply. |